Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
Showing 1,561 - 1,580 results of 21,342 for search '(( significant ((non decrease) OR (point decrease)) ) OR ( significant decrease decrease ))', query time: 0.59s Refine Results
  1. 1561
    Fig 3 -

    Fig 3 - by Razieh Bidhendi-Yarandi (7139387)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1562
    <i>Gpdh1; Ldh</i> double mutants display increased <i>upd3</i> expression.

    <i>Gpdh1; Ldh</i> double mutants display increased <i>upd3</i> expression. by Madhulika Rai (4352803)

    Published 2025
    Save to List
    Saved in:
  3. 1563
    Glucose/galactose with extended interferon-priming does not impact levels of ISG RNAs or non-ISG proteins levels.

    Glucose/galactose with extended interferon-priming does not impact levels of ISG RNAs or non-ISG proteins levels. by Tyron Chang (9922533)

    Published 2024
    Save to List
    Saved in:
  4. 1564
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 1565
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 1566
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 1567
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 1568
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 1569
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 1570
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 1571
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 1572
    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescriptions).

    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  13. 1573
    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n = 269.151prescriptions).

    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  14. 1574
    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.

    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  15. 1575
    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).

    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  16. 1576
    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.814 prescriptions; urologists n = 182.100 prescriptions).

    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  17. 1577
    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.

    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  18. 1578
    UTI diagnoses by sex and physician specialty (2013–2019).

    UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  19. 1579
    Clade body sizes using log transformed mean adult size to represent each turritellid and tegulid species’ size, and typical size to represent the size of each species belonging to Conidae (see Kohn [74] and supplemental text (S1 Text) for additional information on this methodology).

    Clade body sizes using log transformed mean adult size to represent each turritellid and tegulid species’ size, and typical size to represent the size of each species belonging to... by Brendan M. Anderson (11234356)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 1580
    Diversity of each focal taxon in Florida and the Atlantic Coastal Plain throughout the study interval.

    Diversity of each focal taxon in Florida and the Atlantic Coastal Plain throughout the study interval. by Brendan M. Anderson (11234356)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: